ReviewAntibiotics (Basel, Switzerland)2021
How to Combat Gram-Negative Bacteria Using Antimicrobial Peptides: A Challenge or an Unattainable Goal?
Review in Antibiotics (Basel, Switzerland), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 47 citations in OpenAlex.
- Nano-antimicrobial peptides (Nano-AMPs) to combat resistant gram-negative bacteria.Drug delivery and translational research · 2026Review
- Antibiotic loaded solid lipid nanoparticles target bacteria in a pyogenic spondylitis rat model.Discover nano · 2026Article
- Design, Structural Stability, Membrane Binding, and Antibacterial Activity of Novel Antimicrobial Peptides Derived from Wuchuanin-A1.Life (Basel, Switzerland) · 2025Article
- Purification and Characterization of Antimicrobial Peptide from an Epilithic Bacterium Streptomyces sp. AL50 with Activity Against Biofilm Forming Coagulase-Negative Staphylococci.Current microbiology · 2025Article
- Discovery of a Potent Antimicrobial Peptide Through Rational Design: A New Frontier in Pathogen Control.Biomolecules · 2025Article
- Enhanced Gram-Negative Membrane Disruption and In Vivo Efficacy via Lysine-Arginine Enrichment of Opis16a.ACS medicinal chemistry letters · 2025Article
- Experimental and Computational Study of Injectable Iron(III)/Ultrashort Peptide Hydrogels: A Candidate for Ferroptosis-Induced Treatment of Bacterial Infections.Small science · 2025Article
- Emerging antimicrobial therapies for Gram-negative infections in human clinical use.npj antimicrobials and resistance · 2025Review
- Impairing protein-protein interactions in an essential tRNA modification complex: An innovative antimicrobial strategy against Pseudomonas aeruginosa.Journal of peptide science : an official publication of the European Peptide Society · 2025Article
- The effect of C-terminal deamidation on bacterial susceptibility and resistance to modelin-5.European biophysics journal : EBJ · 2025Article
- Influence of Nisin Grafting on the Antibacterial Efficacy of AMP Self-Assembled Monolayers (SAMs).Molecules (Basel, Switzerland) · 2024Article
- Decoding antimicrobial resistance: unraveling molecular mechanisms and targeted strategies.Archives of microbiology · 2024Review
- Study of the Antimicrobial Activity of the Human Peptide SQQ30 against Pathogenic Bacteria.Antibiotics (Basel, Switzerland) · 2024Article
- Lipopolysaccharide targeting-peptide-capped chitosan gold nanoparticles for laser-induced antibacterial activity.Nanomedicine (London, England) · 2024Article
- Altering Escherichia coli envelope integrity by mimicking the lipoprotein RcsF.Archives of microbiology · 2023Article
- Article
- How Alligator Immune Peptides Kill Gram-Negative Bacteria: A Lipid-Scrambling, Squeezing, and Extracting Mechanism Revealed by Theoretical Simulations.International journal of molecular sciences · 2023Article
- Antimicrobial Activity ofVeterinary sciences · 2023Article
- Trichoderma-Mediated ZnO Nanoparticles and Their Antibiofilm and Antibacterial Activities.Journal of fungi (Basel, Switzerland) · 2023Article
- Making a chink in their armor: Current and next-generation antimicrobial strategies against the bacterial cell envelope.Advances in microbial physiology · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Antimicrobial peptides (AMPs) represent a promising and effective alternative for combating pathogens, having some advantages compared to conventional antibiotics. However, AMPs must also contend with complex and specialised Gram-negative bacteria envelops. The variety of lipopolysaccharide and phospholipid composition in Gram-negative bacteria strains and species are decisive characteristics regarding their susceptibility or resistance to AMPs. Such biological and structural barriers have created delays in tuning AMPs to deal with Gram-negative bacteria. This becomes even more acute because little is known about the interaction AMP-Gram-negative bacteria and/or AMPs' physicochemical characteristics, which could lead to obtaining selective molecules against Gram-negative bacteria. As a consequence, available AMPs usually have highly associated haemolytic and/or cytotoxic activity. Only one AMP has so far been FDA approved and another two are currently in clinical trials against Gram-negative bacteria. Such a pessimistic panorama suggests that efforts should be concentrated on the search for new molecules, designs and strategies for combating infection caused by this type of microorganism. This review has therefore been aimed at describing the currently available AMPs for combating Gram-negative bacteria, exploring the characteristics of these bacteria's cell envelop hampering the development of new AMPs, and offers a perspective regarding the challenges for designing new AMPs against Gram-negative bacteria.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.